Interestingly, the Gr1+ neutrophil population greatly increased post BNT162b2-based cancer therapy and was the dominant population in the CD45+PD-L1+ cells in the tumor (Supplementary Fig. S7h, i). This evidence concerns the gene PTPRC and cancer.